- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01498861
Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestradiol
17 maggio 2012 aggiornato da: ViiV Healthcare
A Double-Blind Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Norgestimate and Ethinyl Estradiol When Co-administered With Dolutegravir in Healthy Adult Female Subjects
Dolutegravir (DTG, GSK1349572 is an integrase inhibitor that is currently in Phase 3 clinical development for the treatment of HIV infection.
DTG will likely be used in women on oral contraceptives (OC) for birth control.
Based on accumulated non-clinical and clinical drug metabolism and pharmacokinetic data, there is a low likelihood of drug interaction between DTG and most widely used OC drugs.
The primary objective of this study is to evaluate the effect of DTG administration on the pharmacokinetics and pharmacodynamics of a commonly used oral contraceptive product, Ortho-Cyclen (combination of norgestimate and ethinyl estradiol), in healthy female subjects.
Each subject will participate in a Run-in period (if needed), followed by two treatment periods.
Approximately 16 subjects will be randomized in a cross-over fashion to either Ortho-Cyclen with DTG or Ortho-Cyclen with Placebo for 10 days and switch to the alternate treatment for another 10 days.
Subjects will return to the study center for final follow up evaluations 7 - 14 days after the final dose of study medication.
Panoramica dello studio
Stato
Completato
Condizioni
Intervento / Trattamento
Tipo di studio
Interventistico
Iscrizione (Effettivo)
16
Fase
- Fase 1
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
Florida
-
Miami, Florida, Stati Uniti, 33169
- GSK Investigational Site
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
Da 18 anni a 40 anni (Adulto)
Accetta volontari sani
Sì
Sessi ammissibili allo studio
Femmina
Descrizione
Inclusion Criteria:
- Alanine aminotransferase (ALT), alkaline phosphatase and bilirubin greater than or equal to 1.5 times the upper limit of normal (ULN)
- Healthy female subjects, as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied except for ALT, alkaline phosphatase and bilirubin as above may be included only if the Investigator feels that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
- Female, between 18 and 40 years of age inclusive, at the time of signing the informed consent.
- Women of childbearing potential must use OC Ortho-Cyclen in combination with one of the following appropriate contraceptive methods:a)Complete abstinence from intercourse for at least 14 days prior to the first dose of investigational product (Day 1 of Period 1), throughout the study, and for the subsequent poststudy monitoring or; b) A barrier method plus a spermicide (e.g., condom or diaphragm with spermicidal foam/gel/cream/ suppository for at least 14 days prior to the first dose of investigational product [Day 1 of Period 1]) throughout the study, and for the subsequent poststudy monitoring or; c)Sterilization (vasectomy) of male partner prior to commencement of female subject's last normal menstrual period prior to administration of study drug, and the male partner is the sole partner for that female subject.
- The subject's BMI is 19 to 30 kg/m2 and body weight ≥50 kg (110 lbs) and <114 kg (<250 lbs);
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form;
- Single QTcB < 450 msec; or QTc < 480 msec in subjects with Bundle Branch Block.
Exclusion Criteria:
- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- A positive pre-study drug/alcohol screen.
- A positive test for HIV antibody.
- History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >7 drinks for females. One drink is equivalent to 12 g of alcohol: 12 ounces (360 ml) of beer, 5 ounces (150 ml) of wine or 1.5 ounces (45 ml) of 80 proof distilled spirits.
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
- Women of childbearing potential who are unwilling or unable to use an appropriate method of contraception (see inclusion criteria) from at least 14 days prior to the first dose of investigational product until completion of the follow-up visit;
- Pregnant females as determined by positive hCG test at screening or prior to dosing.
- Lactating females.
- Unwillingness or inability to follow the procedures outlined in the protocol.
- Subject is mentally or legally incapacitated.
- History of any condition that would contraindicate OC administration (including hypertension, stroke, ischemic heart disease, venous thromboembolism or family history of thromboembolism, known factor V Leiden mutation or other gene mutations associated with increased risk of thromboembolism, migraine headaches, carcinoma of the breast, liver or endometrium, gallbladder disease, history of undiagnosed abnormal uterine bleeding, etc.).
- If heparin is used during pharmacokinetic sampling, subjects with a history of sensitivity to heparin or heparin-induced thrombocytopenia.
- Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication.
- Unwilling to abstain from tobacco use from the screening visit until the follow-up visit.
- Females with conditions or concurrent medications that could adversely affect hormone levels e.g. oopherectomies and females receiving drug eluting IUDs (e.g. Mirena).
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Scienza basilare
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Altro: Run-In Period
Ortho-Cyclen for 21 days.
Only for subjects who are not already taking Ortho-Cyclen prior to the study
|
Ortho-cyclen is an oral contraceptive.
|
Sperimentale: Sequence AB
Subjects will take Ortho-Cyclen once a day from Day 1-21 of their menstrual cycle.
In addition they will take dolutegravir 50 mg twice a day from Days 1-10 and placebo twice a day from Day 12-21
|
Ortho-cyclen is an oral contraceptive.
Dolutegravir is an experimental HIV drug
Altri nomi:
Placebo is a tablet with no drug in it
|
Sperimentale: Sequence BA
Subjects will take Ortho-Cyclen once a day from Day 1-21 of their menstrual cycle.
In addition they will take placebo twice a day from Days 1-10 and dolutegravir 50 mg twice a day from Day 12-21
|
Ortho-cyclen is an oral contraceptive.
Dolutegravir is an experimental HIV drug
Altri nomi:
Placebo is a tablet with no drug in it
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
AUC(0-tau) of norelgestromin and ethinylestradiol after Ortho-Cyclen alone and after Ortho-Cyclen with dolutegravir
Lasso di tempo: Up to 24 hours post-dose
|
Samples will be collected at predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours postdose on Days 10 and 21
|
Up to 24 hours post-dose
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Safety and tolerability of all treatments as assessed by vital signs, AEs, and clinical laboratory tests
Lasso di tempo: Up to 8 weeks
|
Up to 8 weeks
|
|
Composite of norelgestromin pharmacokinetic parameters on Day 10 and Day 21: Cmax, Cmin, tmax, tmin and half life
Lasso di tempo: Up to 24 hours post dose
|
Samples will be collected at predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours postdose on Days 10 and 21
|
Up to 24 hours post dose
|
Predose serum levels of luteinizing hormone and follicle stimulating hormone from Periods 1 and 2
Lasso di tempo: predose on Days 1, 10, 11, 21 and 22
|
Samples will be collected at predose on Days 1, 10, 11, 21 and 22
|
predose on Days 1, 10, 11, 21 and 22
|
Predose serum levels of progesterone from Periods 1 and 2
Lasso di tempo: predose on Days 1, 10, 11, 21 and 22
|
Samples will be collected at predose on Days 1, 10, 11, 21 and 22
|
predose on Days 1, 10, 11, 21 and 22
|
Composite of dolutegravir pharmacokinetic parameters on Day 10 and Day 21: AUC(0-t), Cmax, tmax, Cmin, C0, Ct and CL/F
Lasso di tempo: Up to 12 hours post dose
|
Samples will be collected at predose and at 1, 2, 3, 4, 6, 8, and 12 hours post dose on Day 10 and Day 21
|
Up to 12 hours post dose
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio
1 dicembre 2011
Completamento primario (Effettivo)
1 marzo 2012
Completamento dello studio (Effettivo)
1 marzo 2012
Date di iscrizione allo studio
Primo inviato
21 dicembre 2011
Primo inviato che soddisfa i criteri di controllo qualità
21 dicembre 2011
Primo Inserito (Stima)
26 dicembre 2011
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
21 maggio 2012
Ultimo aggiornamento inviato che soddisfa i criteri QC
17 maggio 2012
Ultimo verificato
1 aprile 2012
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Infezioni da virus a RNA
- Malattie virali
- Infezioni
- Infezioni a trasmissione ematica
- Malattie trasmissibili
- Malattie sessualmente trasmissibili, virali
- Malattie trasmesse sessualmente
- Infezioni da lentivirus
- Infezioni da retroviridae
- Sindromi da deficit immunologico
- Malattie del sistema immunitario
- Malattie da virus lenti
- Infezioni da HIV
- Sindrome da immunodeficienza acquisita
- Effetti fisiologici delle droghe
- Meccanismi molecolari dell'azione farmacologica
- Agenti antinfettivi
- Agenti antivirali
- Inibitori enzimatici
- Agenti anti-HIV
- Agenti antiretrovirali
- Agenti antineoplastici
- Inibitori della topoisomerasi II
- Inibitori della topoisomerasi
- Agenti antibatterici
- Agenti contraccettivi, ormonali
- Agenti contraccettivi
- Agenti di controllo riproduttivo
- Contraccettivi, Orali, Combinati
- Contraccettivi, orale
- Agenti contraccettivi, femmina
- Inibitori dell'integrasi dell'HIV
- Inibitori dell'integrasi
- Moxifloxacina
- Norgestimato, combinazione di farmaci etinilestradiolo
- Dolutegravir
Altri numeri di identificazione dello studio
- 111855
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Ortho-Cyclen
-
The University of QueenslandKing's College London; UMC Utrecht; Julius Clinical; FightMNDCompletatoMalattia del motoneurone | Sclerosi laterale amiotroficaOlanda, Regno Unito, Australia
-
Bristol-Myers SquibbCompletato
-
AstraZenecaSospeso
-
Janssen Research & Development, LLCCompletato
-
PBM Healing International LimitedReclutamentoMalocclusione | Trattamento ortodonticoCanada
-
PBM Healing International LimitedCompletatoDolore | OrtodonticoGiappone
-
Bristol-Myers SquibbCompletatoInfezioni da HIVStati Uniti
-
Tianjin Eye HospitalReclutamento
-
MorphotekCompletatoCancro ovarico epitelialeStati Uniti
-
FH ORTHONon ancora reclutamento